Mosnodenvir_product_DataBase

Bioactivity	Mosnodenvir (JNJ-1802) is a pan-serotype dengue antiviral agent with a high barrier to resistance, and is safe and well-tolerated. Mosnodenvir blocks the NS3-NS4B interaction within the viral replication complex. Mosnodenvir shows picomolar to low nanomolar in vitro antiviral activity in mice[1][7].
Target	Dengue virus
Name	Mosnodenvir
CAS	2043343-94-6
Formula	C26H22ClF3N2O6S
Molar Mass	582.98
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Ackaert O, et al. Safety, tolerability and pharmacokinetics of JNJ-1802, a pan-serotype dengue direct antiviral small molecule, in a Phase 1, double-blind, randomized, dose-escalation study in healthy volunteers. Clin Infect Dis. 2023 May 10:ciad284. [2]. Goethals O, Kaptein SJF, Kesteleyn B, Bonfanti JF, Van Wesenbeeck L, Bardiot D, Verschoor EJ, Verstrepen BE, Fagrouch Z, Putnak JR, Kiemel D, Ackaert O, Straetemans R, Lachau-Durand S, Geluykens P, Crabbe M, Thys K, Stoops B, Lenz O, Tambuyzer L, De Meyer S, Dallmeier K, McCracken MK, Gromowski GD, Rutvisuttinunt W, Jarman RG, Karasavvas N, Touret F, Querat G, de Lamballerie X, Chatel-Chaix L, Milligan GN, Beasley DWC, Bourne N, Barrett ADT, Marchand A, Jonckers THM, Raboisson P, Simmen K, Chaltin P, Bartenschlager R, Bogers WM, Neyts J, Van Loock M. Blocking NS3-NS4B interaction inhibits dengue virus in non-human primates. Nature. 2023 Mar;615(7953):678-686.

PeptideDB